Molecular mechanisms of Human Diseases are often regulated by the post-transductional modifications of the proteins. A more effective early diagnosis of the human diseases implies the use of a new generation of molecular tests, highly specific and sensitive, able to assess both native and post-trasductionally modified (PTM) protein biomarkers.

FLUIDIA has developed a proprietary technology ModiQuant Technology that makes possible an easy, quantitative and accurate analysis of native and PTM forms of protein biomarkers in order to improve diagnosis, prognosis and therapy monitoring of human diseases.


The following PTM can be assessed by ModiQuant Technology

  • Phosphorylation
  • Glycosylation
  • Ubiquiotination
  • S-nitrosylation
  • Methylation
  • N-acetylation
  • Lipidation
  • Proteolytic cleavage

ModiQuant approach has been initially conceived to setup multiplexed immunoassays (e.g. ELISA) but it might be potentially miniaturized in microfluidic devices to allow self-assessment of one or more biomarkers.